Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288

Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from both the U.S. FDA and the China CDE, marking a significant milestone in its clinical development for treating relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance from the China CDE follows the earlier approval from the U.S. FDA, indicating strong global development capabilities in targeted protein degradation [1][6]. Group 2: Mechanism of Action and Clinical Need - APG-3288 is a highly potent and selective BTK degrader developed using Ascentage Pharma's proprietary PROTAC technology, designed to induce degradation of both wild-type BTK and multiple BTK mutants associated with resistance to existing BTK inhibitors [4]. - There is a significant clinical need for new drugs with novel mechanisms of action due to the limitations of current BTK inhibitors, which often face issues of acquired resistance [3][4]. Group 3: Company Background and Pipeline - Ascentage Pharma has established a strong presence in the field of hematologic malignancies, with a portfolio that includes approved products like Olverembatinib and Lisaftoclax, enhancing its pipeline in this area [5][9]. - The company is focused on developing innovative therapies to address unmet medical needs in cancer, leveraging its robust R&D capabilities and global partnerships with leading biotechnology and pharmaceutical companies [8][11].